XK
PBYI icon

Xact Kapitalforvaltning’s Puma Biotechnology PBYI Stock Holding History

Xact Kapitalforvaltning’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-4,958
Closed -$227K – 1516
2018
Q3 		$227K Hold
4,958
– – ﹤0.01% 1493
2018
Q2 		$293K Buy
4,958
+500
+11% +$29K 0.01% 1365
2018
Q1 		$303K Buy
4,458
+1,500
+51% +$112K 0.01% 1235
2017
Q4 		$292K Buy
+2,958
New +$331K 0.01% 969

Other funds holding PBYI

State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Xact Kapitalforvaltning's PBYI Position: Q4 2018 in Review

Xact Kapitalforvaltning sold out of Puma Biotechnology (PBYI) in Q4 2018, closing a stake of 4,958 shares — an estimated $227K sold.

Xact Kapitalforvaltning first reported a position in PBYI in Q4 2017 and held it in 4 quarters. The position peaked at $303K in Q1 2018. 141 funds tracked by Wall St. Rank hold PBYI as of Q4 2018.

  • Xact Kapitalforvaltning reported no remaining Puma Biotechnology position as of Q4 2018 after selling out during the quarter.
  • Xact Kapitalforvaltning sold 4,958 Puma Biotechnology shares in Q4 2018, an estimated $227K.
  • Xact Kapitalforvaltning first reported a position in Puma Biotechnology in Q4 2017 and held it in 4 quarters.
  • Xact Kapitalforvaltning's Puma Biotechnology position peaked at $303K in Q1 2018.
  • 141 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2018.

Based on Xact Kapitalforvaltning's 13F filing for Q4 2018, filed 31 Jan 2019.